Orphazyme Aps

Orphazyme (Copenhagen, Denmark) is a biopharmaceutical company focusing on the development of innovative new therapies for the treatment of a family of serious genetic disorders called lysosomal storage diseases. The company’s proprietary approach utilizes the lysosome-protective and stabilizing effect of Heat Shock Proteins as a platform for the development of novel therapies. The lead program, Orph-001, is a recombinant version of human HSP70 and is currently in early pre-clinical development.

Sten Verland


Mobile: +45 24 22 19 69
Email Click here to contact